Skip to content

Innofluidics Diagnostics

Active
Private limited companyfounded 20242 yrs activeAgoralaan Gebouw A, 3590 Diepenbeek, BelgiumKBO/BCE: BE 1007.747.747
Summary

Innofluidics Diagnostics has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3,187 and a net result of €687. Its solvency ranks better than 16% of 536 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.0% (low).

Overview

What they do
Research and development on biotechnology
NACE 72101Engineering and related technical consultancy, excluding land surveyors NACE 71121NACE 72110
1 site
How big
€85,517total assets 2025
Staff
1 FTE
Equity
€3,187
Profit
€687
Turnover not published (abridged schema)
Financially healthy?
49 Fair Checked score 2025
Bankruptcy chance 12 m
1.0%
Who decides
Accounts 4 d early0 of 1 deed read
Why 49- Young company- Weak solvency vs sector+ Lower-failure-rate sectorLatest accounts filed on timeShow the evidence

Checked score

Score 2025
Axes
Profitability70
Solvency29
Growth-
Track record67
Bankruptcy probability, 12 months
1.0% Low
0%0.5%1.5%4%10%≥ 25%
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 y
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 536 sector peers (2025).
NBB · sector comparison
Position among 536 sector peers
Solvency
better than 16%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-07-2026, 4 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
4 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · micro…

Key points

  • Caution: Among the weakest 16% on equitysector median €119,210 · 537 companies €3,187 View
  • Total assets 2025first fiscal year filed €85,517 View
  • Active since 2024founded 28-03-2024 2 years View

By topic

Financials

Fiscal year
2025
Total assets
€85,517
Profit
€687
Solvency
3.7%
Go to Financials

Company details

Sites
1
Legal form
Private limited company
Activity
Research and development on biotechnologyNACE 72101
Founded
28-03-2024
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.